Scaling up Antiretroviral Treatment in the South-East Asia Region

Report of the National AIDS Programme Managers’ Meeting, SEARO, New Delhi, India 19-21 November 2003

WHO Project: ICP HIV 001

World Health Organization
Regional Office for South-East Asia
New Delhi
March 2004
ACRONYMS

AIDS  Acquired Immuno Deficiency Syndrome
ART  Anti Retroviral Treatment
ARV  Anti RetroViral
CCM  Country Coordinated Mechanism
CUP  Condom Use Programme
d4T  Stavudine
GFATM  Global Fund to fight AIDS, Tuberculosis and Malaria
HIV  Human Immunodeficiency Virus
HIV/ TB  The intersecting epidemics of HIV and TB
LFA  Local Fund Agent
NACO  National AIDS Control Organization, India
NAP  National AIDS Programme
NAS  National AIDS Strategy
NGO  Non Governmental Organization
NVP  Nevirapine
OI  Opportunistic Infection
PR  Principal Recipient
RNTCP  Revised National Tuberculosis Programme
RSCM  RS Ciptomangunkusumo Hospital
SEA  South-East Asia
SEAR  South-East Asia Region
SEARO  South East Asia Regional Office
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STI</td>
<td>Sexually Transmitted Infection</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>3TC</td>
<td>Lamivudine</td>
</tr>
<tr>
<td>TRP</td>
<td>Technical Review Panel</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>The joint United Nations programme on HIV/AIDS</td>
</tr>
<tr>
<td>UNGASS</td>
<td>The United Nations General Assembly Special Session on HIV/AIDS</td>
</tr>
<tr>
<td>VCCT</td>
<td>Voluntary Confidential Counselling &amp; Testing (HIV)</td>
</tr>
<tr>
<td>VCT</td>
<td>Voluntary Counselling and Testing (HIV)</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>YRG Care</td>
<td>Y R Gaitonde Centre for AIDS Research and Education</td>
</tr>
<tr>
<td>ZDV</td>
<td>Zidovudine</td>
</tr>
</tbody>
</table>
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>2. INAUGURAL ADDRESS</td>
<td>2</td>
</tr>
<tr>
<td>3. GLOBAL “3 BY 5” INITIATIVE</td>
<td>3</td>
</tr>
<tr>
<td>4. SCALING-UP OF ART IN SOUTH-EAST ASIA: CURRENT STATUS</td>
<td>6</td>
</tr>
<tr>
<td>5. TECHNICAL ISSUES AND CHALLENGES IN SCALING UP ART</td>
<td>7</td>
</tr>
<tr>
<td>5.1 Access to Drugs, Procurement and Supply</td>
<td>7</td>
</tr>
<tr>
<td>5.2 Simplifying Treatment Guidelines</td>
<td>8</td>
</tr>
<tr>
<td>5.3 Treatment Adherence and Antiretroviral Drug Resistance Monitoring</td>
<td>9</td>
</tr>
<tr>
<td>5.4 Laboratory Monitoring of ART</td>
<td>10</td>
</tr>
<tr>
<td>5.5 VCT as an Entry Point for ART</td>
<td>11</td>
</tr>
<tr>
<td>5.6 Involvement of PHAs in ART</td>
<td>12</td>
</tr>
<tr>
<td>6. THE “3 BY 5” INITIATIVE IN THE CONTEXT OF HIV-TB</td>
<td>13</td>
</tr>
<tr>
<td>7. GFATM UPDATE</td>
<td>14</td>
</tr>
<tr>
<td>8. SITUATIONAL ANALYSIS AND PRIORITY ACTIONS FOR SCALING UP ART</td>
<td>15</td>
</tr>
<tr>
<td>8.1 Thailand</td>
<td>15</td>
</tr>
<tr>
<td>8.2 India</td>
<td>17</td>
</tr>
<tr>
<td>8.3 Myanmar</td>
<td>17</td>
</tr>
<tr>
<td>8.4 Indonesia</td>
<td>19</td>
</tr>
<tr>
<td>9. REGIONAL STRATEGY FOR SCALING UP ART</td>
<td>21</td>
</tr>
<tr>
<td>10. SUMMARY AND RECOMMENDATIONS</td>
<td>22</td>
</tr>
<tr>
<td><strong>Annexes</strong></td>
<td></td>
</tr>
<tr>
<td>1. List of Participants</td>
<td>25</td>
</tr>
<tr>
<td>2. Programme</td>
<td>29</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

Globally, five to six million people infected with HIV in the developing world need access to antiretroviral treatment (ART) but only 300,000 are receiving it. The failure to deliver antiretroviral drugs (ARV) to the millions of people who need them is a global health emergency. To address this emergency, WHO is fully committed to getting three million people on ARVs by the end of 2005 - the “3 by 5” target. This is an intermediate target and a means to achieving the treatment goal of universal access to ARVs for all who need them.

In the South-East Asia Region (SEAR), nearly six million people are living with HIV/AIDS making it the second most affected Region in the world after sub-Saharan Africa. Approximately 800,000 people living with HIV/AIDS in the Region are in immediate need of ART; however, less than 30,000 are receiving it. India, Indonesia, Myanmar and Thailand account for an overwhelming majority of the burden of HIV/AIDS in the Region.

Two remarkable developments in the past couple of years have had profound implications for HIV prevention and care around the world. First, the prices of ARV drugs have plummeted to as low as US$ 150 per patient per year, and are expected to further come down as antiretroviral treatment is scaled up in developing countries. Second, experiences in Brazil, Thailand, Botswana and other parts of Africa indicate that it is indeed feasible to implement affordable and replicable ART programmes in resource-poor settings.

Scaling up ART was the central theme of the third National AIDS Programme Managers’ Meeting of the WHO South-East Asia Region held from 19 to 21 November 2003 in New Delhi, India. The meeting was attended by 52 participants including country representatives from Bhutan, DPR Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka,
Thailand and Timor-Leste; nongovernment organizations (MSF, YRG Care); People Living with HIV/AIDS group (INP plus); bilateral donors (DFID, Canadian High Commission); WHO/HQ, SEARO and Country Offices, UNICEF, UNDP and UNAIDS South-Asia Inter-country-team (Annex 1).

The specific objectives of the meeting were:

1. To exchange country experience in scaling-up antiretroviral therapy;
2. To brief the participants on the “3 by 5” initiative proposed by WHO and the partners;
3. To identify priority actions needed to implement “3 by 5” initiatives at country level during 2004-2005;
4. To provide an update on the Global Fund to fight AIDS, TB and Malaria and on issues relating to programme implementation.

The agenda of the three-day meeting is attached (Annex 2).

2. INAUGURAL ADDRESS

The meeting was opened by Dr Poonam Khetrapal Singh, Acting Regional Director, WHO/SEARO. It was stressed that control of HIV/AIDS is one of WHO’s priority programmes and that the “3 by 5” initiative would guide much of WHO’s work on HIV/AIDS. Along with the renewed emphasis on treatment, work on prevention, counselling and care would continue.

The urgent need to increase coverage of quality HIV/AIDS care including ART in the public and private sectors was highlighted. Less than 5% of People Living with HIV/AIDS (PHA) in this Region are receiving ART despite the fact that prices for ARVs have dropped more than 90% in some cases. It is well known that the majority of manufacturers of WHO/UNICEF pre-qualified generic ARVs are from this Region, namely India and Thailand. Thailand is the first country in Asia to set the target of providing more than 50 000 people living with HIV/AIDS with ART by 2005 using different sources for financing.

All efforts must be made to strengthen the capacity of programmes, health services and communities to administer ART. HIV/AIDS prevention efforts must be maintained. The major modes of HIV transmission in the
Region are: sexual transmission, mainly through unprotected sex with commercial sex workers, followed by needle-sharing injecting drug users, and mother to child transmission. Experience in countries of this Region has shown that a number of interventions do work successfully to prevent the spread of HIV. Examples include ensuring targeted condom programmes among commercial sex workers and their clients, combined with the syndromic management of sexually transmitted infections. Prevention of mother-to-child transmission programmes have also been implemented in many countries on a national scale resulting in reduction of HIV/AIDS among children. HIV transmission among IDUs continues to rise in some Member Countries and this must be addressed using harm reduction approaches in tandem with programmes to decrease demand and supply of drugs.

The meeting elected Dr P L Joshi as the Chairman, Dr Manit Teeratantikanont as the Co-chairman and Dr Sujatha Samarakoon as the Rapporteur.

3. **GLOBAL “3 BY 5” INITIATIVE**

While “3 by 5” is a new initiative and WHO’s top priority, it will not replace prevention efforts. Prevention efforts are very important and WHO believes that with a good implementation of ART programme, HIV prevention efforts will also be strengthened. WHO has set a fairly ambitious target and is taking the lead in this initiative, but it cannot do it alone. The “3 by 5” initiative will be driven by countries and by WHO as well as other developmental partners.

WHO’s strategy will be to catalyze rapid uptake of ART in communities by adopting a two-pronged approach:

1. Supporting countries to recognize and respond to their HIV/AIDS treatment gap and leveraging the necessary resources to enable ART to be scaled up rapidly in line with 3x5 target.

2. Simplifying and standardizing ART as far as possible without compromising effectiveness, so that it could be universally scaled up and delivered in resource-constrained settings.

The global strategic framework has 14 elements grouped into five categories, as shown in Table 1.
Table 1: WHO global strategy for “3 by 5”

<table>
<thead>
<tr>
<th>Category 1: WHO and global level activities</th>
<th>Specific Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Visible WHO leadership and commitment to urgent action to reach the goal of universal access to ART.</td>
<td>• Announce the global 3x5 target;</td>
</tr>
<tr>
<td>2. Locate the rights-based 3x5 initiative within the broader development context.</td>
<td>• Declare global health emergency;</td>
</tr>
<tr>
<td>3. Support all national efforts whilst focusing WHO resources on high-burden and strategic countries to achieve maximal impact of 3x5 initiative.</td>
<td>• Allocate resources, with a majority channelled to countries;</td>
</tr>
<tr>
<td>4. Align and mobilize partner support to achieve 3x5 target at global level</td>
<td>• Develop a global strategy and work plan;</td>
</tr>
<tr>
<td></td>
<td>• Revise staff policy to provide ART to all WHO staff</td>
</tr>
<tr>
<td></td>
<td>• Publish ethics and equity guidelines;</td>
</tr>
<tr>
<td></td>
<td>• Respond to appeals from countries for assistance;</td>
</tr>
<tr>
<td></td>
<td>• Increase capacity of WHO country offices by deploying additional, competent staff; and</td>
</tr>
<tr>
<td></td>
<td>• Agree on specific roles with all stakeholders, including the private sector, in the scale-up process and establish mechanisms for ongoing collaboration.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category 2: Country Support Efforts</th>
<th>Specific Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Ensure the key elements required at the national level to deliver the 3x5 target as part of a comprehensive response to HIV/AIDS</td>
<td>• Advocates with countries to set targets in line with 3x5;</td>
</tr>
<tr>
<td>6. Strengthen and support the renewal of health systems and national operational capacity for scaling up ART programmes</td>
<td>• Support countries in the development of national scale-up plans;</td>
</tr>
<tr>
<td>7. Strengthen and build human capacity for scaling up ART</td>
<td>• Broker additional resources to close funding gaps at country level;</td>
</tr>
<tr>
<td>8. Expand capacity of communities to be fully involved in ART programme planning and delivery</td>
<td>• Accelerate HIV prevention activities to reduce stigma and discrimination;</td>
</tr>
<tr>
<td></td>
<td>• Develop technical brief on “Prevention for positives”;</td>
</tr>
<tr>
<td></td>
<td>• Technical and operational guidelines for country implementation;</td>
</tr>
<tr>
<td></td>
<td>• Clinical treatment guidelines (IMAI);</td>
</tr>
<tr>
<td></td>
<td>• Develop methods for accreditation of service delivery points;</td>
</tr>
<tr>
<td></td>
<td>• Develop standardized training packages;</td>
</tr>
<tr>
<td></td>
<td>• Support countries in training of key groups; and</td>
</tr>
<tr>
<td></td>
<td>• Produce guidelines for support quality service provision.</td>
</tr>
<tr>
<td>Strategy</td>
<td>Specific Activities</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------</td>
</tr>
</tbody>
</table>
| **Category 3: Simplified, standardised tools**<br>9. Simplify and standardize procedures to identify individuals in need of therapy and facilitate entry to ART programme<br>10. Simplify and standardize ART to facilitate adherence and enable rapid scale-up to be implemented<br>11. Simplify and standardize tools for tracking ART programme performance including drug resistance surveillance | • Simplified guidelines for HIV counselling and testing;  
• Guidelines for better use of “entry points”;  
• Recommendation for standard first and second line regimens;  
• Guidelines for adherence support;  
• Guidelines on requirements for laboratory monitoring;  
• Guidelines for nutritional support of adults and children on ART;  
• Monitoring and evaluation programme indicators;  
• Guidelines and networks for drug resistance surveillance; and  
• An “incident room” to track activities and progress towards 3x5. |
| **Category 4: Effective, reliable supply of medicines and diagnostics**<br>12. Support country access to, and efficient distribution of high quality, low cost medicines and diagnostics | Form the AMF – AIDS Medicine and Diagnostics Facility - with three major functions:  
a) Provide important information on selection, market intelligence (sources, prices, registration status, patent status, forecasting of needs, forecasting of production capacity), product specification and prequalification;  
b) Arrange for technical support to Member States (market intelligence, procurement, supply management, local production, and  
c) Convene a buyers’ group (common principles, information support, rate tendering, procurement of diagnostics. |
| **Category 5: Success stories and learning by doing**<br>13. Build on success<br>14. Continuously learn by doing - with ongoing evaluation and analysis of programme performance<br>15. and a focused operational research agenda. | • Document experiences and lessons learnt from successful ART programmes (e.g., Brazil, Thailand, Botswana);  
• Document experiences and lessons learnt from other successful programmes (e.g., TB, Polio, SARS);  
• Set up south-to-south networks to disseminate models and exchange information, and  
• Coordinate and develop Operations Research agenda document influence of ART scale up on health systems and impact on prevention and at-risk behaviour. |
4. **SCALING-UP OF ART IN SOUTH-EAST ASIA: CURRENT STATUS**

WHO/SEARO conducted a rapid assessment of country preparedness for scaling-up ART. Seven of the 11 countries in SEAR have included ART in their national AIDS policy and four countries have ARV medicines added to the national essential drug list. Indonesia and Thailand are providing ART through provincial AIDS committees and their respective national programmes. India, Myanmar and Nepal will soon be starting national ART programmes.

All countries except Thailand lack laboratory facilities to perform CD4 counting. VCT and private practitioners are the entry points for the administration of ART in most countries. India and Thailand have the capacity to monitor ARV drug resistance.

Many generic drugs are manufactured in India and Thailand. Drug costs vary from country to country, the lowest price of about US$ 30-50 per month are found in India and Thailand where locally produced generic drugs are being used. Countries have different sources of drug financing ranging from public to private. Strong involvement of civil society including people with HIV/AIDS is necessary in the initiation and implementation of ART at all levels.

Some countries including India, Indonesia, Myanmar, Nepal and Thailand have been successful in mobilizing resources for ARV from the Global Fund, with support from WHO/SEARO. Many meetings on HIV/AIDS care including ARV have been conducted within the Region to enhance implementation at country level and collaboration among partners.

While some ground work has been done, major investments and acceleration of efforts will be required by all partners, in particular high-burden Member Countries such as India, Indonesia, Myanmar and Thailand, to attain the ambitious target of putting 400,000 people on ART.
Table 2: Estimated HIV prevalence and ART needs in SEAR, 2003

<table>
<thead>
<tr>
<th>Country</th>
<th>HIV prevalence</th>
<th>Total number of people needing ART</th>
<th>Number of people on ART in 2003</th>
<th>Proposed WHO target by 2005</th>
<th>Treatment gap (number on treatment and WHO target)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangladesh</td>
<td>13 000</td>
<td>1 800</td>
<td>5</td>
<td>900</td>
<td>895</td>
</tr>
<tr>
<td>Bhutan</td>
<td>&lt;100</td>
<td>14</td>
<td>5</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>DPR Korea</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Indonesia</td>
<td>130 000</td>
<td>18 400</td>
<td>500</td>
<td>9 200</td>
<td>8 700</td>
</tr>
<tr>
<td>India</td>
<td>4 580 000</td>
<td>600 000</td>
<td>13 000</td>
<td>300 000</td>
<td>287 000</td>
</tr>
<tr>
<td>Maldives</td>
<td>100</td>
<td>14</td>
<td>0</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Myanmar</td>
<td>420 000</td>
<td>60 000</td>
<td>1 000</td>
<td>30 000</td>
<td>29 000</td>
</tr>
<tr>
<td>Nepal</td>
<td>60 000</td>
<td>8 000</td>
<td>&lt; 100</td>
<td>4 000</td>
<td>3 750</td>
</tr>
<tr>
<td>Thailand</td>
<td>670 000</td>
<td>98 000</td>
<td>13 000</td>
<td>48 000</td>
<td>25 000</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>4 800</td>
<td>680</td>
<td>25</td>
<td>340</td>
<td>315</td>
</tr>
<tr>
<td>Timor-Leste</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Total</td>
<td>6 million</td>
<td>800 000</td>
<td>30 000</td>
<td>400 000</td>
<td>360 000</td>
</tr>
</tbody>
</table>

5. TECHNICAL ISSUES AND CHALLENGES IN SCALING UP ART

5.1 Access to Drugs, Procurement and Supply

The objective of the procurement and supply system is to ensure that good quality medicines are obtained at competitive prices and the drugs are available without interruption. Supply and procurement systems are influenced by several regulatory regimes, such as, the drug registration system and the intellectual property/patent system. Both of these affect the possible sources of supply, and, therefore, affect access.
Countries like Brazil, Thailand and India have initiated local production of those ARVs that are not protected by a patent in their territory. In addition, Brazil is using the ‘threat’ of issuing a compulsory licence to negotiate steep price reductions for those ARVs that are patented. Several other countries have already implemented small scale or pilot projects. Lessons from their experience include:

- Registration is not a major constraint; usually there is an exemption mechanism, and it is used when necessary. However, while such exemptions are useful in the short term, in the long term, it is preferable to encourage registration. Registration is more secure and reinforces rather than bypasses the drug supply and quality control system.

- Although it might be possible to ignore patents in small-scale or trial projects, when scaling up, the provision of ARVs should have a sound legal basis. Thus, for patented ARVs, countries may have to opt to provide exclusively innovator drugs. Alternatively, they could make use of ‘safeguard mechanisms’ such as compulsory licensing or parallel importation.

Challenges with regard to procurement include inaccurate quantification of requirements; lack of information on prices and sources of good quality medicines and on reliable suppliers; lack of expertise and experience with pharmaceutical procurement and inefficiencies due to procurement being dispersed among several programmes and organizations.

In order to address these challenges, it is important that HIV/AIDS programmes communicate their scaling up targets clearly to procurement offices. Moreover, if at all possible, countries should use experienced procurement officers following good procurement practices and having access to the necessary market intelligence. Countries should also consider pooled procurement, and pooling of procurement expertise.

### 5.2 Simplifying Treatment Guidelines

The present updated and simplified treatment guidelines are the cornerstone of the WHO’s “3-by-5 Strategy”, and are more directive than its predecessor with respect to first and second line therapies. They take into account not only the evidence generated by clinical trials and
observational studies on the efficacy and side effects of the treatment regimens discussed, but also the experience gained with ART by programme and the cost and availability of drugs in resource-limited settings. These guidelines deal only with recommendations for ART and monitoring, but are meant to be a component of a comprehensive package of care at the country level including opportunistic infection prevention and treatment, nutritional programmes, and psychosocial support for infected persons.

The topics addressed in these treatment guidelines include when to start ART, which ARV regimens to start, reasons for changing ART and what regimens to continue if treatment needs to be changed. It also addresses how treatment should be monitored, with specific reference to the side effects of ART and drug adherence, and makes specific recommendations for certain patient subgroups. All recommendations are made bearing in mind the needs of health systems that often lack sophisticated manpower and monitoring facilities, without compromising the quality and outcomes of the treatments offered. A first innovative feature is significant simplification of the recommendations for the treatment regimen, with a recommendation to opt for one, single three-drug first-line treatment regimen, using either d4T or ZDV, 3TC, and either NVP or EFV as the first-line drugs. Further new features include more liberal recommendations on when to start treatment, new definitions of treatment failure, new recommendations on second-line treatment, increased clarity in the laboratory monitoring section, and a new section on adherence support.

5.3 Treatment Adherence and Antiretroviral Drug Resistance Monitoring

Drug compliance is a very important factor in any ART programme. Mechanisms for monitoring of drug adherence and drug resistance should be in place before scaling up ART. Using a fixed drug combination like GPO-vir (d4T/3TC/NVP), as in Thailand, can help improve drug adherence.

Several factors are related to drug adherence, e.g., knowledge about the disease, length and complexity of the treatment; perceived benefits versus barriers; social support; depression; interactions between the patient and the provider; substance use; self-efficacy regarding adherence. From the experience gained by treating patients in YRG Care, poor adherence is
associated with costs of drugs (cannot continue to buy/afford ARV). Therefore, free/subsidized drugs should be important considerations in improving treatment compliance.

Most importantly, national programme managers must ensure that distribution of ARVs occurs in the context of policies, practices and procedures that promote rational ARV use and encourage patient adherence. In collaboration with partners, WHO is in the process of initiating a global ARV drug resistance surveillance programme. The WHO programme will assess geographical and temporal drug resistance prevalence, improve understanding of the factors that lead to resistance, and help identify strategies to minimize the appearance, evolution and spread of drug resistance.

ARV treatment programmes should actively involve patients, their families, PHAs and the communities in improving treatment compliance. In Thailand, advocacy campaigns with key messages are used to improve treatment compliance. Examples of advocacy messages include, “AIDS is a chronic disease like diabetes”, “ART can improve the quality of life of people with HIV”.

Additional research is needed to identify optimal strategies to promote patient adherence. One formidable challenge will be how to get a buy-in from the private sector, where drugs are being provided without monitoring. There is need for national guidelines for simplified and standardized drug regimens to regulate the use of antiretroviral drugs and prevent the emergence of drug resistance.

5.4 Laboratory Monitoring of ART

The role of the laboratory is central for successful ART. Laboratory support is required both to guarantee safe and effective drug treatment and assess ARV drug resistance. Flow cytometry is the gold standard for CD4+ count measurement and is the recommended method; however, it is extremely expensive and requires infrastructure and trained human resources.

Issues and challenges for laboratory support of ART include development of uniform guidelines, creation of infrastructure, cost of equipment, continuous supply of reagents, quality assurance, training of human resources, and ongoing operations research. Back up of laboratory
support is extremely important - e.g. generator, continuous supply of resources, reagents, trained laboratory workers. Good management is very important at all levels of the programme. The high cost of maintenance of machines is also an issue - the cost of annual maintenance for big machines is up to 6-7% of its total cost. Another important area is quality assurance of both public and private laboratories. Private laboratories are dominated by market forces and would require external quality control through a method of accreditation to ensure that the quality of diagnostics is not compromised.

WHO is supporting Member Countries by developing regional guidelines, training human resources in CD4 count and quality assurance, providing technical support to countries in creating infrastructure and networking, promotion of quality systems, and resource mobilization.

Diagnostic technology is evolving at a rapid pace. Countries must strengthen their health systems and be ready to absorb the new technology without worrying too much about the cost at this point. It is likely that cost of diagnostics will eventually come down. Networking of laboratories (at different levels, and across different sectors) is required to overcome resource limitations. Brazil is a successful example of optimally creating a laboratory network for ARV. Brazil has a network of 70 laboratories for assessing viral load, 63 laboratories for CD4 count, and has placed on treatment more than 100,000 patients.

5.5 VCT as an Entry Point for ART

India’s National AIDS Control Organisation (NACO) has been establishing Voluntary Counselling and Testing (VCT) Centres since 1997, initially attached to blood banks. Over the past three years, the number of VCTs has rapidly accelerated from 108 in 2001 to 445 in 2002. As of December 2003, 542 VCT Centres have been established in all districts in high prevalence states and are being progressively established in districts in low prevalence states. NACO aims to establish at least one VCT in each district of India by 2004. Each VCT is staffed with two counsellors (one male and one female), one laboratory technician and with the appropriate infrastructure and consumables for HIV testing. However, currently, only 30-40% of VCTs are functioning according to national guidelines.
In 2002, a total number of 425,205 clients were tested in VCTs in India. 24% were voluntary walk-in clients, 62% of all clients tested received pre-test counseling and around 13% of all clients tested positive for HIV.

Selected high prevalence states (Andhra Pradesh, Karnataka) have established VCTs at the sub-district level using state level funds. The third round of GFATM funding is earmarked for the establishment of sub-district level VCTs in rural areas of all six high prevalence states (Andhra Pradesh, Karnataka, Maharashtra, Manipur, Nagaland, Tamil Nadu) in close coordination with the RNTCP (Revised National TB Control Programme).

A pilot study on TB-HIV collaborative activities from six high HIV prevalence states conducted over nine months until August 2003 followed 249,386 new VCCT clients. 20% of these clients were HIV-positive. 41% of HIV positive clients (with cough) had been referred to TB Microscopy Centres and 38% of the referred HIV-positive clients also had TB.

5.6 Involvement of PHAs in ART

PHAs are no longer just passive consumers of health care, but should be involved actively in providing care and support to peers. In scaling up of ART, PHAs can play a crucial role and reduce workload on health staff by motivating other PHAs to come forward for treatment, and by supporting treatment adherence. For this, they would need to be trained in ARV, opportunistic infections, communication skills, and recording and reporting. National programmes should take concerted steps to develop and support PHA networks.

PHAs play an important role both in policy development and implementation in the ART programme. In Thailand, MSF successfully collaborated with PHAs and this experience could be used by other countries. Involvement of PHAs in the co Trimoxazole prophylaxis campaign was a key stepping stone in the collaboration. In India, the government is providing funds to PHA groups to set up networks. As a result, 14 states in India have a network of PHAs. ARV is increasingly being identified as a need by PHAs. In Indonesia, NGOs are playing an important role in engaging PHAs, particularly IDUs.
Several issues still need to be addressed. ART gives PHAs a second life. So they want to get back to work, have relationships, and have sex and family. In order to ensure long-term adherence, it would be important to address these issues.

6. THE “3 BY 5” INITIATIVE IN THE CONTEXT OF HIV-TB

The South-East Asia Region bears 40% of the global TB burden and ranks second after sub-Saharan Africa in the number of HIV/AIDS cases. HIV-TB is an important priority in the Region. Collaboration between HIV and TB programmes are beginning to take shape in several countries based on a clear and comprehensive policy and strategy on HIV-TB. The “3 by 5” initiative provides considerable additional opportunities to enhance HIV/TB collaboration.

The TB programmes and the DOTS strategy in countries have a well established system of drug delivery that can serve as a model for ARV delivery. TB patients in high HIV settings are likely to be co-infected. They constitute a readily identifiable group in the health system for HIV testing and ART thus can contribute strongly to the “3 by 5” target. Draft guidelines for treatment of HIV/TB co-infection are being finalized (Table 3).

**Table 3: Recommended treatment strategy for patients with TB disease and HIV co-infection**

<table>
<thead>
<tr>
<th>CD4 (mm3)</th>
<th>TB and ART</th>
<th>Recommend</th>
</tr>
</thead>
</table>
| < 200     | 1. Start TB Rx  
            2. Start ART as soon TB Rx tolerated | Recommend ART |
| 200 - 350 | 1. Start TB Rx  
            2. Start ART after initiation phase | Consider ART |
| > 350     | Start TB Rx | Defer ART |


It is important to learn how lessons from TB can be packaged for scaling up ART. Examples of successful lessons from the TB programme
include the setting of national targets for coverage of services and adherence to treatment; simplified and standardized diagnosis and treatment approach, the use of community resources for improving treatment adherence, including the use of family members with supervision from the health system; ensuring uninterrupted drug supply, and tracking progress against targets by quarterly cohort analysis.

7. **GFATM UPDATE**

Since the Global Fund was established in 2001, the WHO Regional Office has been providing support to Member Countries in terms of information and communication, technical assistance in proposal development and implementation, convening regional meetings, and organizing mock Technical Review Panels (TRPs).

To date, US$ 409,595,687 have been committed to HIV/AIDS programmes in the SEA Region through the Global Fund (Table 4). The national governments are the main Principal Recipients (PRs) in the countries. However, in Myanmar and DPR Korea, the PR is unknown. Given the need for additional and ongoing technical assistance from WHO requiring staff commitment and resources, Country Coordination Mechanism (CCMs) may be encouraged to request funding to be set aside during grant agreement negotiations, to support multilateral agencies such as WHO to undertake operational, advisory and monitoring and evaluation services as required by countries during the implementation stage.

Table 4. Proposals approved and funds allocated to South-East Asia Region

<table>
<thead>
<tr>
<th>Component</th>
<th>Round 1</th>
<th>Round 2</th>
<th>Round 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangladesh AIDS</td>
<td>19,961,030</td>
<td></td>
<td></td>
</tr>
<tr>
<td>India AIDS</td>
<td>100,081,000</td>
<td>14,819,773</td>
<td></td>
</tr>
<tr>
<td>HIV/TB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia AIDS</td>
<td>15,960,103</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myanmar AIDS</td>
<td></td>
<td>54,300,034</td>
<td></td>
</tr>
</tbody>
</table>
### APPROVED BUDGET

<table>
<thead>
<tr>
<th>Component</th>
<th>Round 1</th>
<th>Round 2</th>
<th>Round 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nepal AIDS</td>
<td></td>
<td>11 173 542</td>
<td></td>
</tr>
<tr>
<td>Thailand AIDS</td>
<td>109 505 316</td>
<td>81 348 535</td>
<td>1 371 348</td>
</tr>
<tr>
<td>MMR-THA NGO AIDS</td>
<td>1 075 006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>126 540 425</td>
<td>212 564 107</td>
<td>70 491 155</td>
</tr>
<tr>
<td>Total (Round 1, 2 &amp; 3):</td>
<td>409 595 687</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The pre-requisite for PRs to set up credible financial systems and build up new supply distribution systems before the first disbursements for medicine purchases has caused many delays between grant agreements and disbursements. Another concern is the high costs of international Local Fund Agents (LFAs) versus local options. The Global Fund intends to award a number of Local Fund Agent Framework Contracts and invites suitably qualified organizations to submit proposals for provision of services as LFA. The discussion that other kinds of organizations besides private sector accounting firms should also be considered as LFA is ongoing.

The fourth round of GF will be primarily a “3 by 5” round. Calls for applications will be made by the first week of April 2004 and the deadline for submission would be the first week of April. Technical support missions will be made available from the Regional Office and regional review and mock TRP will be provided.

In summary, GF presents an excellent opportunity to mobilize resources; priority will be given to ensure GF support for countries without approved proposals. Countries with approved proposals need to build PR capacity and ensure performance-based implementation.

### SITUATIONAL ANALYSIS AND PRIORITY ACTIONS FOR SCALING UP ART IN HIGH BURDEN COUNTRIES

#### 8. Thailand

More than 1 million people have been infected with HIV to date causing an estimated 450 742 deaths. While a declining trend in the number of new
HIV infections is noted in the recent years, it is expected that more than 50,000 AIDS cases will continue to occur each year for the next five years due to the large number of those already infected with HIV.

To mitigate the impact of the epidemic, the ART programme in Thailand began as early as 1992. The programme was developed in three phases: in the first phase (1992-1997), AZT monotherapy was introduced and a limited number of cases were treated at a few sites. In the second phase (1998-2000), the capacity and networking of clinical service centres were strengthened with the strategy to integrate ARV into a comprehensive care and support programme. Dual therapy was introduced as a standard treatment in 1998 before changing to ART in 2000. The number of patients accessible to the therapy, however, was still limited. In the third phase, it has been possible to expand the ART programme due to lowered prices and local production of generic medicines.

Currently, the National Access to ARV Programme aims to cover all cases who are in need of ARV. The core components of the programme include: simplified standard regimens (d4T+3TC+nevirapine as the first line of treatment); infrastructure development and capacity building through continuous training for medical doctors, nurses, counsellors or social workers, laboratory technicians and pharmacists; drug procurement and distribution; monitoring and evaluation of ARV programme; development of CD4 count laboratory networks; and involvement of civil society, PHA and family care givers in improving adherence to treatment.

More than 800 hospitals are currently involved in providing ARVs. Up to September 2003, 14,677 patients have been initiated on ARV, of whom 13,279 are currently on treatment. The government allocated US$ 25 million in 2004 to scale up access from 13,000 to 50,000 next year. The policy has been laid to provide ARV to cover all AIDS patients through the Social Security Fund and Universal Health Insurance programme. Necessary infrastructure development including human resource development will be built up. Currently there are 19 CD4 machines available for ARV in 19 centres. This year, an additional 20 centres will come up from GF to support expansion of ART. The cost of diagnosis and monitoring is still very high. 80% of the required budget for ARV would come from the government and the rest from the Global Fund.
The challenges and priority actions remaining for ensuring ARV access to all include sustaining the programme by building capacity, strengthening partnerships, maintaining financial commitment, reduction of cost for CD4 count, adherence to ARV, long term follow-up, surveillance for clinical failure and drug resistance.

8.2 India

There are an estimated 4.58 million persons living with HIV/AIDS. It is estimated that around 13 000 PHA are receiving ART in the private sector. The public sector provides free ARVs (under certain circumstances) in the Central Health Services, ESI (Employees State Insurance Scheme), and the Ministry of Defence. The government supports provision of ARV for post-exposure prophylaxis in Government hospitals and for the Prevention of Parent to Child Transmission programme for preventive treatment.

Scaling up treatment to 300 000 PHAs who need treatment will be a challenging task and will require the following urgent actions: (1) development of a national policy on ART; (2) sensitization of the political and administrative leadership and other stakeholders; (3) development of a strategic national plan for scaling up ART; (4) mobilization of financial resources in conjunction with partners; (5) exploration of mechanisms to procure generic drugs and strengthen existing systems for distribution and inventory control; (6) development or adaptation of guidelines for diagnosis, treatment, and monitoring; (7) development of plans for capacity building of medical, paramedical and programme staff; (8) mobilization of communities, PHA networks and other international and national partners, and (9) review of existing monitoring and evaluation plan to include indicators for monitoring ART.

8.3 Myanmar

A total of 45 033 people in Myanmar were diagnosed with HIV infection up to December 2002, although it is estimated by UNAIDS that between 170 000 and 420 000 people are currently living with HIV/AIDS. Access to treatments for opportunistic infections and antiretroviral combination therapy is currently very limited due to resource constraints.
HIV/AIDS along with TB and malaria is among the three priority diseases addressed in the National Health Plan. The government has increased funding for AIDS/STD programme five fold in the past three years to 22.5 million Kyats and plans to increase this thrice in the next four years (73.9 million Kyats).

There are 40 AIDS/STD prevention and control teams in 30 towns (including Yangon) covering 28 districts. The teams of eight people consist of doctors, nurses, nurse assistants, counsellors/health educators, and laboratory technicians. The teams are based in public sector STD clinics. The teams provide outreach education, VCCT, STI diagnosis and treatment, contact tracing, local administration of the 100% CUP, PMCT services (in some sites), sentinel surveillance, HIV outpatients treatment (including drugs for opportunistic infections), and home care. Currently 35 districts do not have prevention and control teams.

In these districts, local medical officers provide limited HIV/AIDS/STI services. Over the next five years, AIDS/STD prevention and control teams will be established in each of the 35 districts not currently covered. The salary component of the planned expansion will be funded by the NAP, as part of the budgetary commitment of the Myanmar Government to responding to HIV/AIDS/STIs.

Three priority areas have been identified to be urgently addressed with the support of the Global Fund:

1. To reduce the risk of HIV infection through sexual transmission by expansion of the 100% Condom Use Programme (CUP);
2. To reduce the risk of HIV infection among injecting drug users through a range of harm reduction interventions, and
3. To build capacity for voluntary confidential counselling, HIV testing (VCCT), and care and support including ART services.

The expansion and promotion of VCCT services to 200 towns nationwide over five years will be used to very significantly increase the number of people in ‘at risk’ groups and the general population who will have ready access to HIV counselling and testing. VCCT services have been designed as an entry point to enable the direct delivery of education and
prevention messages and linking people who are infected with care and treatment services, including access to ART and OI treatments. Expected results will be a reduction in HIV transmission through education and prevention, and improved access to care and support services resulting in a better quality of life. Number of PLWHA receiving ART will cover 550 persons during the first year, 2,619 in the second year and up to 6,548 by the fifth year.

8.4 Indonesia

There are an estimated 90,000 – 130,000 PLWHA in Indonesia. The Ministry of Health is increasingly engaging the local governments and other stakeholders in mobilizing financial and human resources for comprehensive HIV/AIDS activities, including ART. There are currently 30 ART delivery points in Indonesia. To date, an estimated 1,100 PHAs have been put on ART. In terms of diagnostic capacity, there are currently two CD4 centres, both in Jakarta. Drug adherence monitoring has not yet been initiated.

At present, the cost of ART is around Rp. 500,000 – 650,000/month. Cost of ART support is considered through three mechanisms: 1) 100% support from government through the social safety net, i.e., free service for poor with poverty card; 2) 50% subsidy, and 3) full payment by patients themselves. Currently, 90% of patients are paying by themselves. The government has committed to allocate subsidy funding for 2,000 patients @ Rp 200,000/month in the year 2004.

The government plans to set up reference hospitals for HIV/AIDS management, including facilities for CD4 count in at least six priority provinces (Jakarta, Bali, Riau, Papua, West Java - Bandung, and East Java - Surabaya), where HIV prevalence is highest. The government will work closely with NGOs and the drug dependence hospitals to scale up access to IDUs.

The RSCM under the assistance of the Pokdisus has long initiated HIV/AIDS care and now is expanding its commitment to act as a training hospital for other groups of HIV care providers from various parts of Indonesia. Training in laboratory procedure is also being followed through WHO support and national level training will follow to strengthen
laboratory support. Some medical professionals have been sent to regional collaborating training centres through WHO assistance and Indonesia has a plan to send at least 20 health care providers as soon as possible to build capacity in ART provision. VCT training modules have been developed and massive training of counsellors needs to be scaled up.

Indonesia recognizes the urgent need to be ready for treatment, care and support of PHAs, and has already identified it as an important and priority need in the NAS as well as the MoH National AIDS Strategy. However, it is also recognized that it is important to have technical guidelines, tools and sufficient capacity for delivering of such a programme. The WHO commitment and proposed leadership is very timely and very much appreciated.

At present, 1100 PHAs are already on ARV through community support and it’s expected that by the end of 2005, at least 10 000 will be on ARVs if appropriate support is available. Priority activities for Indonesia will be as follows:

(1) To mobilize national political commitment for Indonesia’s partnership and contribution to reach the WHO 3 by 5 target. This advocacy is essential, as Indonesia has a decentralized system, which means that local governments have a major decision-making power.

(2) To develop a comprehensive plan including monitoring and evaluation, and partnership plans will have to be developed by end January 2004.

(3) To build the capacity of health services to deliver ART. While WHO is already involving some Indonesian personnel in regional training, the country will need to build a massive pool of human resources with good understanding of the right approach to scaling up ART.

(4) To identify a focal agency and develop a system and coordination mechanisms with partners for ensuring uninterrupted supply of ARV and diagnostics.

(5) To develop national guidelines for treatment, adherence, monitoring as proposed in the regional strategic framework.

(6) To establish monitoring, evaluation, surveillance and operational research.
9. **REGIONAL STRATEGY FOR SCALING UP ART**

To attain the ambitious target of putting 400 000 people in the Region on ART will require major investments and acceleration of efforts by all partners in other high-burden Member Countries, such as India, Indonesia, Myanmar and Thailand. Currently in SEAR, only 30 000 PHAs are on antiretroviral treatment against a target of 400 000. Thus, treatment coverage has to be scaled by a factor of 10 by 2005.

The success of the regional strategy for scaling-up ART depends on the implementation of a policy package which includes the following six strategy elements:

1. **High-level government commitment to scaling-up ART aiming at 50% coverage** and ultimately at universal coverage. Effective leadership requires a permanent national core group for scaling-up ART qualified in the planning and management of the treatment programme. The core group’s tasks are to initiate, coordinate, supervise and evaluate the key activities of the treatment programme at all levels through the primary health care system wherever it exists. The team should consist of partners from government, technical experts, nongovernmental organizations, private medical associations, civil society, PHAs, international partners and donors.

2. **Establishment of a system of regular drug supply of all essential first-line and second line ARV.** Advanced planning for drug procurement and timely delivery should be based on the targeted number of patients and stock levels. Stock outs must not occur, since treatment interruptions will result in the emergence of drug resistance.

3. **Building capacity of health services to deliver through the development, strengthening and sustaining of the workforce.** A capacity building plan must be developed to ensure the availability of sufficient number of appropriately qualified individuals for the scale-up and maintenance of ART services for 400 000 people by the end of 2005.
(4) **Mechanisms for proper case management to ensuring treatment adherence.** Service delivery models, peer support, increasing treatment literacy of People Living with HIV/AIDS, in order to avoid the emergence of resistant HIV strains should be developed. This is of utmost importance, since only a limited number of ARVs for second line treatment are available in Member Countries.

(5) **Community mobilization including People Living with HIV/AIDS.** Reducing stigma and discrimination through community mobilization, establishing community groups and ensuring their involvement in planning, and overseeing enrollment, service delivery and treatment adherence, establishing referral/linkages between services within health facilities and between health facility and home/community, and increasing demand for VCT including prevention, care and treatment through social mobilization are necessary.

(6) **Establishment and maintenance of a monitoring, evaluation, and surveillance system as well as operational research to be used for programme supervision and evaluation.** This system should be based on recording individual patient information in registers and on regularly reporting, preferably on a quarterly basis at district level. The flow of data to central level and feedback as well as the analysis of data at all levels must be determined. ARV drug resistance surveillance at national level is recommended.

**10. SUMMARY AND RECOMMENDATIONS**

The meeting concluded that scaling-up of antiretroviral treatment will be a part of the comprehensive care package for PHAs and reaffirmed that HIV prevention efforts will be maintained. Participants worked in smaller groups to initiate work plans for starting and scaling-up ART which will be fine-tuned and submitted to WHO in due course.

**For WHO and other developmental partners:**

(1) While maintaining its overall support for HIV prevention activities, WHO should fully advocate for “3 by 5”, the setting of national targets and the development of national strategic plans.
(2) Full-fledged technical support for antiretroviral treatment should be provided to the four high burden countries (India, Thailand, Myanmar and Indonesia) while ensuring sustained support to all countries in the Region for comprehensive HIV prevention and care, including ART.

(3) Mechanisms for intercountry exchange of information and experiences should be established and reinforced, lessons learned for “3 by 5” documented.

(4) Development of tools and guidelines for voluntary counseling and testing, clinical management, drug management, and monitoring and evaluation should be finalized; their distribution to countries expedited, and provide assistance in adaptation and application of these tools and guidelines, as necessary, for country use.

(5) Countries should be supported to strengthen capacity for the core technical and programmatic areas, specifically monitoring, supervision and evaluation of care and treatment programmes, and in identifying priority areas for operational research.

(6) WHO should assist Countries in advocacy for additional financial support to fill the current funding gaps, and help them in preparing proposals for the fourth round of GFATM, where requested.

(7) Staff capacity at the regional and country levels should be strengthened to support efforts to achieve the “3 by 5” target.

For Member States:

(1) National targets should be set for the number of people living with HIV/AIDS to receive antiretroviral treatment by 2005, in line with the global target of 3 million by 2005 (i.e., at least 50% coverage of the persons requiring treatment).

(2) Comprehensive national plans and strategies for the “3 by 5” target should be developed by strengthening the existing health care systems.
(3) PLWHAs, NGOs, and civil society, media and the private sector, and international partners should be fully involved in planning, implementation and evaluation of HIV/AIDS care with an emphasis on equitable access.

(4) Uninterrupted supply should be ensured with sufficient buffer stock of diagnostics, antiretroviral drugs and other supportive treatment (drugs for prevention and treatment of opportunistic infections).

(5) Comprehensive mechanisms for adherence to antiretroviral treatment and drug resistance monitoring should be included in the national plans.

(6) Increased national resources should be allocated and additional external resources mobilized in order to ensure adequate and sustainable financing and access to HIV/AIDS care and antiretroviral treatment.

(7) Strategic plans should be implemented for capacity building, targeting programme managers, medical doctors, counsellors, nurses, paramedics, laboratory technicians, pharmacists and PHAs.

(8) Monitoring and evaluation indicators recommended by WHO and other partners should be adopted in order to monitor coverage and quality of services.
Annex 1
LIST OF PARTICIPANTS

Country Representatives

**Bhutan**
Mr Tshewang Dorji
Programme Officer, STD/AIDS
Department of Public Health
Thimphu
Tel: 00975-2-321842
Fax: 00975-2-326038/323527
Email: tdorji15@hotmail.com

**DPR Korea**
Dr Kim Jong Hwan
National HIV/AIDS Program Manager
Ministry of Health
Pyongyang
Dr Ju Hyon IK
Interpreter
Ministry of Health
Pyongyang

**India**
Dr P L Joshi
Additional Project Director
National AIDS Control Organization (NACO)
Ministry of Health and Family Welfare
New Delhi – 110011
Tel: 011-23325337
Fax: 011-23731746
Email: doctorjoshi@yahoo.com
Dr A S Rathore
Joint Director (Training)
National AIDS Control Organisation (NACO)
Ministry of Health and Family Welfare
36, Janpath
New Delhi – 110001
Tel: 011-23736851
Fax: 011-23731746
Email: asr_naco@yahoo.com
Dr J P Wali
Consultant
National AIDS Control Organization (NACO)
Ministry of Health and Family Welfare
36, Janpath
New Delhi - 110001
Tel: 011-23325335
Mob: 9810336715
Fax: 011-23731746
Email: jpwali@hotmail.com
Dr Ranjeet S Virk
Consultant
National AIDS Control Organization (NACO)
Ministry of Health and Family Welfare
36, Janpath
New Delhi – 110001
Tel: 011-23325335
Mob: 9810219131
Fax: 011-23731746
Email: ranjit_virk@hotmail.com

**Indonesia**
Dr Santoso Suroso
Director, Prof Sulianti Saroso Infectious Disease Hospital
Jl. Sunter Permai Raya
Jakarta 14340
Tel: 62-021-6401411
Fax: 62-021-6401411
Email: santoso@infeksi.com
Dr Saiful Jazan
Chief of STD/HIV/AIDS Subdirectorate
Jl Percetakan Negara
Jakarta Pusat
Tel: 62-21-42880231
Fax: 62-21-42880231
Email: subdit_aidspms@yahoo.com
Dr Samsuridjal Djauzi  
Director of Dharmais Cancer Hospital & Coordinator  
Diagnosis and Therapy Access Programme  
Faculty of Medicine, University of Indonesia  
National Hospital Dr Cipto Mangunkusumo Jakarta 13220  
Tel: 62-21-5681580  
Fax: 62-21-3904546  
Email: s-djauzi@hotmail.com

Maldives  
Mr Mohamed Rameez  
AIDS Programme Manager  
Department of Public Health Male'  
Tel: 960-32-7236  
Fax: 960-31-4635  
Email: dphinfo@dhivehinet.net.mv

Myanmar  
Dr Le Le Win  
Team Leader, AIDS/STD  
27 B, U Lon Maung Street Yangon  
Tel: 95-01-666872  
Email: myothiri@yangon.mm

Dr Mar Mar Aye  
Medical Officer  
Mandalay General Hospital Mandalay  
Tel: 0953-25040

Dr Htin Aung  
Team Leader, AIDS/STD  
469, Tall Street, Pyay Bago Division  
Tel: 0953-25040

Nepal  
Dr Ram Prasad Shrestha  
Director, National Centre for STD/AIDS Control  
Teku, Dotts Complex Kathmandu  
Tel: 977-1-4261653  
Fax: 977-1-4261406  
Email: ncasc@ntc.net.com, rps@info.com.np

Dr Laxmi Bikram Thapa  
Senior Physician  
STA Infectious Disease Hospital Teku Kathmandu  
Tel/Fax: 977-1-4253395  
Email: labl_thapa@hotmail.com

Sri Lanka  
Dr Iyanti Abeyewickreme  
Director  
National STD/AIDS Control Programme  
P O Box 567 Colombo  
Tel: 94-11-2695183  
Fax: 94-11-5336873  
Email: dir-nscap@itmin.com

Dr Sujatha Samarakoon  
Consultant Venereologist  
STD/AIDS Control Programme  
29, De Saram Place Colombo 8  
Tel: 94-11-2693123  
Fax: 94-11-400321  
Email: sujatha1@itmin.com

Thailand  
Dr Manit Teeratantikanont  
Deputy Director-General  
Department of Disease Control  
Ministry of Public Health Muang District Nonthaburi  
Tel: 066-25918395  
Fax: 066-25903276  
Email: manit@health.moph.go.th

Dr Sombat Thanprasertsuk  
Director, Bureau of AIDS, TB, STIs  
Department of Disease Control  
Ministry of Public Health Tiwanon Road Nonthaburi 11000  
Tel: 66-21918411  
Fax: 66-25918413  
Email: sombat@aidsthai.org
Timor-Leste
Dr Avelino Guterres Gorreia
National HIV/AIDS Council
University of Dili
Dili
Tel: 670-7234841

Partner Agencies
Dr Emelia Timpo
Team Leader
UNAIDS South Asia Intercountry Team
EP 16/17
Chandragupta Marg
Chanakyapuri
New Delhi-110021
Tel: 24104970-73 Ext. 42
Fax: 24103534
Email: emelia.timpo@undp.org

Ms Rie Debabrata
Programme Officer
UNDP Regional HIV & Development Project
South & NE Asia
13, Jor Bagh
New Delhi 110003
Tel: 011-24620618
Email: rie.debabrata@undp.org

Dr Bir Singh
Project Officer, PPTCT
HIV/AIDS Section
UNICEF, India Country Office
73, Lodhi Estate
New Delhi-110003
Tel: 011-24690401
Fax: 011-24691410
Email: bsingh@unicef.org

Ms Eileen Stewart
First Secretary
Canadian High Commission
Chanakyapuri
New Delhi
Tel: 011-51782045

Mr Desmond Whyms
Health Adviser
DFID India
B-28, Tara Crescent
Qutub Institutional Area
New Delhi-110016
India
Tel: 011-26529123
Fax: 011-26529296
Email: d-whyms@dtid.gov.uk

Temporary Advisors
Prof. Taimor Nawaz
Professor of Medicine
Bangladesh Medical College
Road 14/A, Dhanmondi
Dhaka 1209
Bangladesh
Tel: 88-018240-828
Fax: 88-029125-655
Email: bmch@bangla.net

Mr Abraham Kurien
President, INP+
Flat No. 6, Kash Towers
93, South West Boag Road
T-Nagar, Chennai 600017
Tel: 044-2432-9580
Fax: 044-2432-9582
Email: inpplus@vsnl.com

Dr N Kumarasamy
Chief Medical Officer & Clinical Researcher
YRG Care Centre for AIDS Research and
Education VHS
Taramani, Chennai 600 113
India
Tel: 044-31006962
Fax: 044-22542939
Email: kumarasamy@yrgcare.org

Dr David Wilson
Medical Coordinator
MSF
Thailand
Tel: 66-1-987-3241
Fax: 66-2-731-1432
Email: mfsbthai@ksc.th.com
WHO Secretariat

WHO/HQ
Dr Gottfried Hirnschall
Coordinator
Department of HIV/AIDS
World Health Organization
Avenue Appia 20
1211 Geneva
Switzerland
Tel: 41-22-791-2915
Fax: 41-22-7912111
Email: hirnschallg@who.int

Dr Gilles Poumerol
Country Support Team (TSH)
Department of HIV/AIDS
World Health Organization
Avenue Appia 20
1211 Geneva
Switzerland
Tel: 41-22-791-2915
Fax: 41-22-7912111
Email: poumerolg@who.int

WHO Country Offices

Dr Amaya Maw-Naing
Medical Officer (HIV/AIDS)
c/o WHO Representative to Indonesia
Jakarta

Dr Hemamal Jayawardena
Short-term Professional (HIV/AIDS)
c/o WHO Representative to Bangladesh
Dhaka

Ms Karin Timmermans
Short-term Professional (EDM)
c/o WHO Representative to Indonesia
Jakarta

Dr Sampath Krishnan
National Professional Officer (Communicable Diseases Surveillance)
Office of WHO Representative to India
New Delhi

Dr K. Ravi Kumar
National Professional Officer (Malaria)
Office of WHO Representative to India
New Delhi

Ms Laksami Suebsaeng
National Professional Officer (HIV/AIDS)
Office of WHO Representative to Thailand
Bangkok

WHO/SEARO

Dr Poonam Khetrapal Singh
Ag. Regional Director/Deputy Regional Director

Dr N Kumara Rai
Director, Department of Communicable Diseases

Dr U Than Sein
Director, Department of Evidence and Information for Policy

Dr Abdul Sattar Yoosuf
Director, Department of Sustainable Development & Healthy Environments

Dr M. Khalillulah
Ag. Director, Department of Family and Community Health

Mr Daniel Walter
Ag. Director, Department of Administration and Finance

Dr Jai P Narain
Coordinator (HIV/AIDS, TB and Other Communicable Diseases)

Dr Sawat Ramaboot
Coordinator (Health Promotion)

Dr Neena Raina
Regional Adviser, ADH

Dr Tej Walia
Regional Adviser, HSD

Dr Rajesh Bhatia
Ag. Regional Adviser, BCT

Dr Khalilur Rahman
Ag. Regional Adviser (Health Promotion & Education)

Dr Ying-Ru Lo
Medical Officer (AIDS)

Dr Renu Garg
Short-term Professional (Epidemiology)
Annex 2

PROGRAMME

Monday, 19 November 2003

0900-1230 hrs
• Welcome/Opening remarks – Poonam Khetrapal Singh, DRD/SEARO
• Objectives of the meeting – Jai P Narain, Coordinator(HIVAIDS & TB), SEARO
• Sharing global, regional and country experience with ART (15 min. presentations)
  - Global “3 by 5” initiative – WHO HQ
  - Progress made in SEAR – Jai P Narain, WHO SEARO
  - Progress made in Thailand – NAP Thailand

1400-1700 hrs
• Discussion
• “3 by 5 initiative”: Issues and challenges for scaling up ART (Presentations 15 minutes)
  - New simplified treatment regimens – Ying-Ru Lo, WHO SEARO
  - Access to drugs, procurement and supply – Karin Timmermann, WHO Indonesia

Tuesday, 20 November 2003

0900-1230 hrs
• “3 by 5” initiative: Issues and challenges for scaling up ART (Presentations 15 minutes)
  - Simplified laboratory monitoring of ART (CD4, TLC) – Sudarshan Kumari, WHO SEARO
  - Involvement of PHA and communities for ensuring treatment adherence – Paisan Tan-Ud TNP Plus, David Wilson MSF
  - Treatment adherence and ARV drug resistance – N. Kumarasamy, India
• Country missions
• Check list for country missions
  WHO HQ /WHO SEARO

1400-1700 hrs Group Work
• To identify priorities for action at country level during 2004-2005, followed by Country presentations
• Synthesis of country workplans Rapporteur
• GFATM update - Jai P. Narain, WHO SEARO

Wednesday, 21 November 2003

0900-1230 hrs
• Welcome/Opening remarks *
  DRD, SEARO
• Objectives of the meeting
  Jai Narain, Coordinator HIV/AIDS &TB, SEARO
• Global “3 By 5” strategy
  WHO HQ
• Country target and needs in four priority countries
  - India
  - Thailand
  - Myanmar
  - Indonesia
• Conclusions and Recommendations
  Jai P. Narain, WHO/SEARO
• Closing of NAP Meeting
  N Kumara Rai, WHO/SEARO